BioAegis Therapeutics, Inc.
BioAegis Therapeutics Inc. is a newly formed, clinical stage entity developing novel protein replacement therapies based on plasma gelsolin.
BioAegis is a newly formed, Phase 2 company commercializing biomarker-driven therapies based on recent groundbreaking discoveries of Dr. Thomas Stossel, Harvard Med./Brigham and Womens. Products involve plasma gelsolin, a human protein for replacement therapy with a unique profile of protecting against inflammation while supporting immunity. Ph1b/2a data in critical care. This funding achieves US IND-ready with manufacturing and diagnostic.